Holen Sie sich die Stockscreener-App
9.268
9.61%
0.818
Schlusskurs vom Vortag:
$8.45
Offen:
$8.54
24-Stunden-Volumen:
793.47K
Relative Volume:
0.91
Marktkapitalisierung:
$478.56M
Einnahmen:
$676.80M
Nettoeinkommen (Verlust:
$-8.60M
KGV:
-32.76
EPS:
-0.2829
Netto-Cashflow:
$135.40M
1W Leistung:
+14.92%
1M Leistung:
+15.34%
6M Leistung:
-16.18%
1J Leistung:
+44.72%
1-Tages-Spanne:
$8.52
$9.285
1-Wochen-Bereich:
$8.061
$9.268
52-Wochen-Spanne:
$5.615
$14.06
Emergent Biosolutions Inc Stock (EBS) Company Profile
Firmenname
Emergent Biosolutions Inc
Sektor
Telefon
240-631-3200
Adresse
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
9.275 | 435.99M | 676.80M | -8.60M | 135.40M | -0.2829 |
TAK
Takeda Pharmaceutical Co Adr
|
15.87 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.26 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.74 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.81 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
578.01 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-03-07 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-08-29 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-04-10 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Eingeleitet | The Benchmark Company | Buy |
| 2021-02-24 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-07-31 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-09-04 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Hochstufung | Goldman | Neutral → Buy |
| 2018-08-03 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-06-13 | Eingeleitet | Argus | Buy |
| 2018-04-25 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2018-01-16 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | Singular Research | Buy |
| 2016-04-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-03-28 | Eingeleitet | Singular Research | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2014-05-15 | Eingeleitet | Summer Street Research | Buy |
| 2011-05-31 | Bestätigt | WBB Securities | Strong Buy |
| 2011-01-10 | Bestätigt | Wedbush | Outperform |
| 2010-11-05 | Bestätigt | Wedbush | Outperform |
| 2010-08-18 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Bestätigt | Caris & Company | Buy |
Alle ansehen
Emergent Biosolutions Inc Aktie (EBS) Neueste Nachrichten
EBS Stock Price, Quote & Chart | EMERGENT BIOSOLUTIONS INC (NYSE:EBS) - ChartMill
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization - Insider Monkey
Emergent BioSolutions to Participate in Upcoming Investor Conferences - The Manila Times
Emergent Biosolutions donates thousands of NARCAN Nasal Spray units across the U.S. since 2021 - Traders Union
Emergent BioSolutions (EBS) Secures ACAM2000 Approval in Saudi A - GuruFocus
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live] - marketscreener.com
Saudi Arabia approves smallpox and mpox vaccine for people at high risk - Stock Titan
Emergent BioSolutions Inc. Common Stock (NYSE:EBS) Stock Quote - The Chronicle-Journal
Global governments turn to Emergent Biosolutions for crisis health preparedness - Traders Union
Q4 2025 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Q1 2026 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
EBS Technical Analysis | Trend, Signals & Chart Patterns | EMERGENT BIOSOLUTIONS INC (NYSE:EBS) - ChartMill
EBS Stock Chart | EMERGENT BIOSOLUTIONS INC (NYSE:EBS) - ChartMill
Emergent BioSolutions Inc. Common Stock (NY: EBS - FinancialContent
SABS: SAB-142 progresses in phase II-B with robust funding and regulatory clarity, targeting type 1 diabetes - TradingView
EBS SEC FilingsEmergent Biosolutions Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Emergent outlines $170M-$185M Q2 revenue outlook while maintaining $720M-$760M 2026 revenue guidance - MSN
Emergent BioSolutions Inc. (EBS): Investor Outlook with a Promising 31.43% Potential Upside - DirectorsTalk Interviews
Tranche Update on Emergent BioSolutions Inc.'s Equity Buyback Plan announced on May 7, 2025. - marketscreener.com
Travel Vaccines Market Size is Projected to Reach US$ 5,914.22 - openPR.com
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Harsanyi Zsolt - Moomoo
SAB Biotherapeutics and Emergent BioSolutions Sign Manufacturing and Supply Agreement for Drug Product Development - Minichart
MSN Money - MSN
Emergent BioSolutions Announces Preliminary 2012 Financial Results and Provides Guidance for 2013 - AOL.com
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director Fowler Neal Franklin - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director Zoon Kathryn C - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director Richard Ronald - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director FOWLER JOHN D JR - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director White Marvin L - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director DeGolyer Donald W - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director Dayal Sujata Tyagi - Moomoo
Emergent BioSolutions director Keith Katkin sells $128,182 in stock By Investing.com - Investing.com Australia
Singapore approves Emergent's ACAM2000 for high-risk mpox use - Stock Titan
Emergent BioSolutions director Dayal sells $115,610 in stock By Investing.com - Investing.com South Africa
Emergent BioSolutions director DeGolyer sells $129,993 in shares By Investing.com - Investing.com South Africa
Emergent BioSolutions director Dayal sells $115,610 in stock - Investing.com
Emergent BioSolutions director Keith Katkin sells $128,182 in stock - Investing.com
Emergent BioSolutions (NYSE: EBS) director nets stock awards, tax-driven share sales - Stock Titan
Emergent BioSolutions (NYSE: EBS) director sells shares and receives new grants - Stock Titan
Emergent BioSolutions (NYSE: EBS) director sells shares and receives RSUs, options - Stock Titan
Director Marvin White (NYSE: EBS) receives RSU and stock option awards - Stock Titan
Emergent BioSolutions (EBS) director granted RSUs and stock options for board service - Stock Titan
Director at Emergent BioSolutions (NYSE: EBS) receives RSU and option grants - Stock Titan
Emergent BioSolutions (NYSE: EBS) director sells shares, receives new awards - Stock Titan
Emergent BioSolutions (EBS) director granted RSUs and stock options in annual award - Stock Titan
Emergent BioSolutions (NYSE: EBS) chair granted RSUs and stock options as board pay - Stock Titan
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142 - Bioscience Association Manitoba
H.C. Wainwright Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Emergent BioSolutions (EBS) Q1 EPS Profit Challenges Narrative Of Persistent Losses - Sahm
Finanzdaten der Emergent Biosolutions Inc-Aktie (EBS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):